Read by QxMD icon Read

Stage I seminoma

Martin Fehr, Angela Fischer Maranta, Hermann Reichegger, Silke Gillessen, Richard Cathomas
Introduction: The practice of carboplatin dosing is not concordant among different centres and oncologists. Some clinical guidelines recommend capping of the carboplatin dose at, for example, creatinine-clearance (Crea-Cl) of 125 mL/min because of concerns of excessive toxicity. Clinical data to support such recommendations are lacking, especially in patients with seminoma. Methods: This is a retrospective analysis of acute haematotoxicity of patients with stage I seminoma treated with adjuvant carboplatin area under the curve (AUC) 7 in routine practice in two Swiss centres in 2005-2015, and a comparison of incidence and grade (according to Common Terminology Criteria for Adverse Events v4...
2018: ESMO Open
Aditya Jain, Catherine Degnin, Yiyi Chen, Mike Craycraft, Arthur Hung, Jerry Jaboin, Charles R Thomas, Timur Mitin
PURPOSE: Most men with stage I testicular seminoma are cured with surgery alone, which is a preferred strategy per national guidelines. The current pattern of practice among US radiation oncologists (ROs) is unknown. MATERIALS AND METHODS: We surveyed practicing US ROs via an online questionnaire. Respondent's characteristics, self-rated knowledge, perceived patient compliance rates with observation were analyzed for association with treatment recommendations. RESULTS: We received 353 responses from ROs, of whom 23% considered themselves experts...
March 9, 2018: International Braz J Urol: Official Journal of the Brazilian Society of Urology
Axel John, André Baumgart, Thomas Worst, Julia Heinzelbecker
OBJECTIVE: The study aimed to calculate direct medical costs (DMC) during the first year of diagnosis and to evaluate the impact of guideline changes on treatment costs in clinical stage (CS) I testicular germ cell tumor (TGCT) patients in a German healthcare system. MATERIALS AND METHODS: Healthcare expenditures as DMC during the first year of diagnosis for 307 TGCT patients in CS I treated at our institution from 1987 to 2013 were calculated from the statutory health insurance perspective using patient level data...
March 7, 2018: Urologia Internationalis
Rune A W van de Wetering, Stefan Sleijfer, Darren R Feldman, Samuel A Funt, George J Bosl, Ronald de Wit
No abstract text is available yet for this article.
February 1, 2018: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
Hester Lieng, Padraig Warde, Philippe Bedard, Robert J Hamilton, Aaron R Hansen, Michael A S Jewett, Martin O'malley, Joan Sweet, Peter Chung
Testicular seminoma most commonly affects young men and is associated with favourable prognosis. Various followup schedules and imaging protocols for testicular seminoma have been described without overall consensus. We reviewed the literature together with our experience at the Princess Margaret Cancer Centre and present an evidence-based followup approach for patients with stage I and II seminoma.
December 1, 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
C Overs, J B Beauval, L Mourey, P Rischmann, M Soulié, M Roumiguié, Nicolas Doumerc
INTRODUCTION: Surgical treatment of post-chemotherapy residual mass of germ cell tumor (GCT) may be performed in various techniques. We assess the feasibility, safety, and efficacy of single-docking with lateral approach robot-assisted retroperitoneal lymph node dissection (R-RPLND) in residual mass of GCT in our center. MATERIALS AND METHODS: A retrospective review of patients undergoing R-RPLND for residual mass of CGT was performed between January 2014 and April 2017...
January 20, 2018: World Journal of Urology
Michal Chovanec, Lucia Vasilkova, Lucia Setteyova, Jana Obertova, Patrik Palacka, Katarina Rejlekova, Zuzana Sycova-Mila, Katarina Kalavska, Daniela Svetlovska, Silvia Cingelova, Beata Mladosievicova, Jozef Mardiak, Michal Mego
BACKGROUND: Treatment for cancer may lead to development of cognitive difficulties in cancer survivors. This study aimed to evaluate long-term cognitive functioning (CogF) in germ-cell tumor (GCT) survivors. Subjects, Materials, and Methods. GCT survivors (n = 155) from the National Cancer Institute of Slovakia completed the Functional Assessment of Cancer Therapy Cognitive Function at a median of 10 years of follow-up (range: 5-32). The study group consisted of survivors receiving a cisplatin-based chemotherapy, radiotherapy to the retroperitoneal lymph nodes, or both, whereas the control group included survivors treated with orchiectomy only...
January 19, 2018: Oncologist
Carl M Post, Aditya Jain, Catherine Degnin, Yiyi Chen, Mike Craycraft, Arthur Y Hung, Jerry J Jaboin, Charles R Thomas, Timur Mitin
PURPOSE: Patients with testicular seminoma may face fertility issues because of their underlying disease as well as treatments they undergo. The current patterns of practice among U.S. radiation oncologists aimed at assessing and preserving fertility in patients with Stage I seminoma are unknown. METHODS: We surveyed practicing U.S. radiation oncologists via an Institutional Review Board-approved online questionnaire. Respondents' characteristics and perceived patient infertility rates were analyzed for association with treatment recommendations...
January 16, 2018: Journal of Adolescent and Young Adult Oncology
Hester Lieng, Peter Chung, Tony Lam, Padraig Warde, Tim Craig
PURPOSE: Limited data exist on testicular dose measurements using modern radiation treatment techniques and volumes for testicular seminoma. The aim of this study was to report the testicular dose using in vivo measurements in men with testicular seminoma receiving abdominopelvic radiation therapy (APRT) and a modified dog-leg field with and without gonadal shielding. METHODS AND MATERIALS: Men with histologically confirmed testicular seminoma, either newly diagnosed stage II disease or isolated retroperitoneal relapse on surveillance for stage I disease, treated with APRT had testicular dose measurements recorded using MOSFET dosimeters...
January 3, 2018: Practical Radiation Oncology
Ildar V Gainetdinov, Yulia V Skvortsova, Sofia A Kondratieva, Alexey Klimov, Alexey A Tryakin, Tatyana L Azhikina
BACKGROUND: Aberrant overexpression of PIWI/piRNA pathway proteins is shown for many types of tumors. Interestingly, these proteins are downregulated in testicular germ cell tumors (TGCTs) compared to normal testis tissues. Here, we used germline and TGCT markers to assess the piRNA biogenesis and function in TGCTs and their precursor germ cell neoplasia in situ (GCNIS). METHODS: We used small RNA deep sequencing, qRT-PCR, and mining public RNAseq/small RNA-seq datasets to examine PIWI/piRNA gene expression and piRNA biogenesis at four stages of TGCT development: (i) germ cells in healthy testis tissues, (ii) germ cells in testis tissues adjacent to TGCTs, (iii) GCNIS cells and (iv) TGCT cells...
January 4, 2018: BMC Cancer
P Maroto, G Anguera, C Martin
Testicular germ-cell cancer (GCC) is a curable disease. Stage I patients are mostly cured by surgery alone. For those with good prognosis advanced disease, radiotherapy in some patients with stage II Seminoma and chemotherapy for all other patients, are responsible for 95% of long-term survivors. Unfortunately, despite this high level of curability, overall survival has been reported lower for those patients receiving either radiotherapy or chemotherapy versus patients treated by surgery alone. Long-term survivors face a higher incidence of second neoplasms, and a higher risk of cardiovascular disease and metabolic syndrome than expected...
January 2018: Critical Reviews in Oncology/hematology
Satoshi Washino, Tsuzumi Konishi, Kimitoshi Saito, Masashi Ohshima, Yuhki Nakamura, Tomoaki Miyagawa
A late-relapse germ cell tumor might contain malignant non-germ cell tumors, known as 'somatic-type malignancy (SM)'. The development of a secondary SM is rare, and this phenomenon remains poorly understood. Case 1 developed lung metastasis 13 years after chemotherapy followed by retroperitoneal lymph node dissection for stage IIA non-seminoma. The tumor increased in size after chemotherapy. The patient underwent a pneumonectomy. Pathology revealed an adenocarcinoma with immature teratoma. The patient has experienced no relapse for 9 years...
November 2017: Journal of Surgical Case Reports
M Anjanappa, A Kumar, S Mathews, J Joseph, K M Jagathnathkrishna, F V James
AIM: This study aims to identify clinical features, treatment outcomes, and prognostic factors for relapse and survival in patients with testicular seminoma. MATERIALS AND METHODS: Retrospective analysis of all patients with pure seminoma treated at our center during over a decade (January 2005-December 2014) was carried out. Patient demographics, tumor characteristics, and treatment details and pattern of recurrence were recorded in a structured format, and disease-free survival and overall survival were calculated...
January 2017: Indian Journal of Cancer
Joanna Jonska-Gmyrek, Piotr Peczkowski, Wojciech Michalski, Grazyna Poniatowska, Agnieszka Zolciak-Siwinska, Beata Kotowicz, Pawel Wiechno, Magdalena Golawska, Maria Kowalska, Tomasz Demkow
Testicular germ cell tumours (GCT) represent about 1-2% of malignant in men. The essential therapeutic option for early-stage GCT is radical orchiectomy (RO), except in situations that require immediate chemotherapy in patients with a massive dissemination and unequivocally elevated levels of tumour markers. Postoperative radiotherapy (PORT) in patients with testicular seminoma in Clinical Stage I (CS I) is one of the treatment options next to active surveillance (AS) and chemotherapy (CHTH). Regardless of the procedure, five-year survival in this group of patients ranges between 97% and 100%...
2017: Contemporary Oncology Współczesna Onkologia
Tomislav Omrcen, Andrija Katic, Eduard Vrdoljak
PURPOSE: To analyze the role of a multidisciplinary team (MDT) in the decision-making process in clinical stage one (CS I) testicular cancer (TC). METHODS: We retrospectively evaluated data on 115 consecutive patients with CS I TC (excluding stage IS) who were referred to the Department of Oncology, University Hospital of Split, Croatia, from 2003 to 2012. Fifty-six patients (48.7%) were referred between 2003 and 2007, before the introduction of the MDT and 59 patients (51...
September 2017: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
Joost L Boormans, Javier Mayor de Castro, Lorenzo Marconi, Yuhong Yuan, M Pilar Laguna Pes, Carsten Bokemeyer, Nicola Nicolai, Ferran Algaba, Jan Oldenburg, Peter Albers
CONTEXT: Patients with clinical stage I (CS I) seminoma testis with large primary tumours and/or rete testis invasion (RTI) might have an increased risk of relapse. In recent years, these risk factors have frequently been employed to decide on adjuvant treatment. OBJECTIVE: To systematically review the literature on tumour size and RTI as risk factors for relapse in CS I seminoma testis patients under surveillance. EVIDENCE ACQUISITION: Relevant databases including Medline, Embase, and the Cochrane Library were searched up to November 2016...
November 20, 2017: European Urology
N Adra, L H Einhorn, S K Althouse, N R Ammakkanavar, D Musapatika, C Albany, D Vaughn, N H Hanna
Background: Despite remarkable results with salvage standard-dose or high-dose chemotherapy about 15% of patients with relapsed germ-cell tumors (GCT) are incurable. Immune checkpoint inhibitors have produced significant remission in multiple tumor types. We report the first study of immunotherapy in patients with GCT. Patients and Methods: Single arm phase 2 trial investigating pembrolizumab 200mg IV Q3weeks until disease progression in patients with relapsed GCT and no curable options...
October 17, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
Glenda Scandura, Clare Verrill, Andrew Protheroe, Johnson Joseph, Wendy Ansell, Anju Sahdev, Jonathan Shamash, Daniel M Berney
OBJECTIVE: To investigate the pathology of excised testicular lesions <10 mm in size. PATIENTS AND METHODS: The pathological reports of 2 681 patients with testicular lesions from Barts Health NHS Trust and Oxford University Hospitals NHS Foundation Trust were reviewed as part of a service evaluation audit from January 2003 to May 2016. Cases in which the lesion had a maximum diameter of <10 mm were selected. Clinical features were also accessed, where available, to examine patient demographics, prediagnostic levels of serum markers, ultrasonographic findings and clinical details...
October 15, 2017: BJU International
Hiten D Patel, Gregory A Joice, Zeyad R Schwen, Alice Semerjian, Ridwan Alam, Arnav Srivastava, Mohamad E Allaf, Phillip M Pierorazio
PURPOSE: While retroperitoneal lymph node dissection (RPLND) is traditionally reserved for nonseminomatous germ cell tumors, recent efforts to reduce long-term toxicities of radiation and chemotherapy have turned attention to its application for testicular seminomas. Currently, RPLND is reserved for the post-chemotherapy for stage II testicular seminomas; we aimed to describe current utilization of RPNLD for testicular seminomas by stage and implications for survival. METHODS: A national sample of men diagnosed with stage IA/IB/IS/IIA/IIB/IIC testicular seminoma (1988-2013) was evaluated from SEER Program registries...
January 2018: World Journal of Urology
Lucia Nappi, Craig R Nichols, Christian K Kollmannsberger
Clinical stage I represents the most frequent presentation of both seminoma and nonseminoma testicular cancer. Despite a survival rate of close to 100%, the management of patients with this disease stage is controversial. The recurrence rate is 10% to 20% for patients with stage I seminoma and 15% to 50% for those with stage I nonseminoma. A highly sensitive and specific biomarker of relapse that is applicable to both seminoma and nonseminoma, and able to drive a definitive risk-adapted management of the patients, still is not available...
August 2017: Clinical Advances in Hematology & Oncology: H&O
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"